ProQR Doses First Patient in Phase 2/3 ILLUMINATE Trial of Sepofarsen for LCA10 Press release LEIDEN, The Netherlands and CAMBRIDGE, Mass., April 15, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. april 15, 2019
ProQR Doses First Patient in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2 Press release LEIDEN, Netherlands and CAMBRIDGE, Mass., March 11, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. maart 11, 2019
ProQR Completes Dosing of Cystic Fibrosis Patients in QR-010 Phase 1b Trial Press release Key Updates augustus 29, 2017
ProQR to present QR-010 data at the European Cystic Fibrosis Society Conference and provides an update on the ongoing Phase 1b trial Press release Key Updates juni 08, 2017
ProQR to Release Topline Data from Proof of Concept Study of QR-010 in Cystic Fibrosis Patients at NACFC Press release LEIDEN, the Netherlands, June 21, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. juni 21, 2016
ProQR spins out all Dystrophic Epidermolysis Bullosa activities into newly formed Wings Therapeutics created by EB Research Partnership Press release LEIDEN, Netherlands and CAMBRIDGE, Mass., March 26, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. maart 26, 2019
ProQR Announces Presentations and Investor & Analyst Event at the North American Cystic Fibrosis Conference Press release LEIDEN, the Netherlands, Oct. 24, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. oktober 24, 2017
ProQR spins out Amylon Therapeutics as a privately-held company focused on central nervous system (CNS) therapeutics Press release Key updates september 12, 2017
ProQR Receives Fast Track Designation from the FDA for QR-110 for Leber’s Congenital Amaurosis Type 10 Press release Key Updates mei 31, 2017
ProQR Announces Clearance of IND Application to Start Clinical Trial for QR-110 in Leber’s Congenital Amaurosis Type 10 Patients Press release Key updates april 27, 2017